List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6209998/publications.pdf

Version: 2024-02-01



Μαρττι Πάλρα

#	Article	IF	CITATIONS
1	Agents that increase the permeability of the outer membrane. Microbiological Reviews, 1992, 56, 395-411.	10.1	1,468
2	Agents that increase the permeability of the outer membrane Microbiological Reviews, 1992, 56, 395-411.	10.1	925
3	Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature, 1983, 303, 526-528.	27.8	232
4	Polycations sensitize enteric bacteria to antibiotics. Antimicrobial Agents and Chemotherapy, 1983, 24, 107-113.	3.2	216
5	Characterization of the lipopolysaccharide from the polymyxinâ€resistant <i>pmrA</i> mutants of <i>Salmonella typhimurium</i> . FEBS Letters, 1981, 129, 145-149.	2.8	198
6	Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy, 1996, 40, 1801-1805.	3.2	188
7	Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coii are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Molecular Microbiology, 1995, 16, 271-278.	2.5	185
8	Increased substitution of phosphate groups in lipopolysaccharides and lipid A of the polymyxin-resistant pmrA mutants of Salmonella typhimurium: a31P-NMR study. Molecular Microbiology, 1994, 11, 481-487.	2.5	162
9	Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrobial Agents and Chemotherapy, 1993, 37, 2255-2260.	3.2	160
10	Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy, 1993, 37, 354-356.	3.2	151
11	Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents. Antimicrobial Agents and Chemotherapy, 2008, 52, 3229-3236.	3.2	126
12	New approaches in peptide antibiotics. Current Opinion in Pharmacology, 2009, 9, 571-576.	3.5	119
13	Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	118
14	Outer Membrane Permeability Barrier in <i>Escherichia coli</i> Mutants That Are Defective in the Late Acyltransferases of Lipid A Biosynthesis. Antimicrobial Agents and Chemotherapy, 1999, 43, 1459-1462.	3.2	113
15	Outer Membrane Permeability Barrier Disruption by Polymyxin in Polymyxin-Susceptible and -Resistant <i>Salmonella typhimurium</i> . Antimicrobial Agents and Chemotherapy, 1981, 19, 578-583.	3.2	109
16	Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrobial Agents and Chemotherapy, 1984, 25, 701-705.	3.2	103
17	A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane. Antimicrobial Agents and Chemotherapy, 2010, 54, 3341-3346.	3.2	103
18	Increased outer membrane resistance to ethylenediaminetetraacetate and cations in novel lipid A mutants. Journal of Bacteriology, 1981, 148, 426-434.	2.2	102

#	Article	IF	CITATIONS
19	Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics. Molecules, 2019, 24, 249.	3.8	95
20	Polymyxins and their novel derivatives. Current Opinion in Microbiology, 2010, 13, 574-581.	5.1	87
21	Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium. Journal of Bacteriology, 1979, 139, 664-667.	2.2	85
22	Novel derivatives of polymyxins. Journal of Antimicrobial Chemotherapy, 2013, 68, 1213-1219.	3.0	79
23	Two Improved Methods for Obtaining Axenic Cultures of Cyanobacteria. Applied and Environmental Microbiology, 1979, 38, 1011-1014.	3.1	75
24	Poor Antibacterial Effect of RopivacaineÂ. Anesthesiology, 1999, 91, 884-884.	2.5	73
25	Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Frontiers in Microbiology, 2019, 10, 1689.	3.5	71
26	Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity. JCl Insight, 2018, 3, .	5.0	60
27	Effect of small cationic leukocyte peptides (defensins) on the permeability barrier of the outer membrane. Infection and Immunity, 1988, 56, 2324-2329.	2.2	50
28	Sodium hexametaphosphate sensitizes Pseudomonas aeruginosa, several other species of Pseudomonas, and Escherichia coli to hydrophobic drugs. Antimicrobial Agents and Chemotherapy, 1989, 33, 1741-1747.	3.2	48
29	rfaP mutants of Salmonella typhimurium. FEBS Journal, 1989, 185, 541-546.	0.2	45
30	Ability of cecropin B to penetrate the enterobacterial outer membrane. Antimicrobial Agents and Chemotherapy, 1994, 38, 2498-2501.	3.2	44
31	Eight bacterial proteins, including UDP-N-acetylglucosamine acyltransferase (LpxA) and three other transferases of Escherichia coli, consist of a six-residue periodicity theme. FEMS Microbiology Letters, 1992, 97, 249-254.	1.8	43
32	An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. Journal of Immunology, 1984, 132, 2582-9.	0.8	43
33	Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides, 2012, 35, 248-252.	2.4	39
34	Rapid Molecular Characterization of Acinetobacter baumannii Clones with rep-PCR and Evaluation of Carbapenemase Genes by New Multiplex PCR in Hospital District of Helsinki and Uusimaa. PLoS ONE, 2014, 9, e85854.	2.5	38
35	Bacterial â€ [~] histone-like protein l' (HLP-I) is an outer membrane constituent?. FEBS Letters, 1990, 262, 123-126.	2.8	37
36	A Novel Enzyme Application for Corn Wet Milling. Starch/Staerke, 1988, 40, 409-411.	2.1	34

#	Article	IF	CITATIONS
37	Overgrowth of Enterococcus faecium in the Feces of Patients with Hematologic Malignancies. Clinical Infectious Diseases, 1996, 23, 694-697.	5.8	33
38	Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. Journal of Antimicrobial Chemotherapy, 2009, 64, 1067-1070.	3.0	32
39	New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin. Medicinal Research Reviews, 2018, 38, 1661-1673.	10.5	32
40	The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. International Journal of Antimicrobial Agents, 2013, 41, 292-293.	2.5	30
41	Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 942-945.	3.0	29
42	Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. Journal of Antimicrobial Chemotherapy, 2010, 65, 981-985.	3.0	27
43	Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. Journal of Antimicrobial Chemotherapy, 2013, 68, 636-639.	3.0	27
44	Structure–activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides, 2010, 31, 2318-2321.	2.4	24
45	Antimicrobial susceptibility of Salmonella typhimurium carrying the outer membrane permeability mutation SS-B. Antimicrobial Agents and Chemotherapy, 1990, 34, 853-857.	3.2	22
46	Chemical Structure of the Lipid A Component of Lipopolysaccharides of the Genus Pectinatus. FEBS Journal, 1994, 224, 63-70.	0.2	21
47	Structure–activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity. Peptides, 2017, 91, 8-12.	2.4	20
48	Preferential synthesis of heptaacyl lipopolysaccharide by the ssc permeability mutant of Salmonella typhimurium. FEBS Journal, 1992, 204, 1101-1106.	0.2	17
49	Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. Journal of Antimicrobial Chemotherapy, 2018, 73, 452-455.	3.0	17
50	Susceptibility of Gram-negative bacteria to the synergistic bactericidal action of serum and polymyxin B nonapeptide. Canadian Journal of Microbiology, 1986, 32, 66-69.	1.7	16
51	First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009. Eurosurveillance, 2009, 14, .	7.0	16
52	Defective biosynthesis of the lipid A component of temperature-sensitive firA (omsA) Mutant of Escherichia coli. FEBS Journal, 1993, 212, 363-369.	0.2	15
53	Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005 \hat{a} *2013: a population-based analysis. Prostate Cancer and Prostatic Diseases, 2016, 19, 417-422.	3.9	14
54	Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gramâ€Negative Bacteria. ChemMedChem, 2016, 11, 2511-2521.	3.2	14

#	Article	IF	CITATIONS
55	The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii. Peptides, 2019, 112, 149-153.	2.4	13
56	The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drugs Under Experimental and Clinical Research, 1991, 17, 437-43.	0.3	12
57	Phosphate groups in lipopolysaccharides ofSalmonella typhimurium rfaPmutants. FEBS Letters, 1997, 409, 457-460.	2.8	9
58	Low Levels of Cytokines and Endotoxin in a Fatal Case of Myocardial Depression and Septic Shock Due to Yersinia pseudotuberculosis. Scandinavian Journal of Infectious Diseases, 1995, 27, 533-535.	1.5	4
59	Non-tuberculous Mycobacteria can Cause Disseminated Mycobacteriosis in Cats. Journal of Comparative Pathology, 2018, 160, 1-9.	0.4	3
60	Evaluation of Antimicrobial Therapy of Blood Culture Positive Healthcare-Associated Infections in Children. PLoS ONE, 2015, 10, e0141555.	2.5	2
61	Polymyxins Targeting the Outer Membrane of Gram-negative Bacteria. Medicinal Chemistry Reviews, 2016, , 243-258.	0.1	2
62	Do salicylates and ascorbate increase the outer membrane permeability to hydrophobic antibiotics in Pseudomonas aeruginosa?. Drugs Under Experimental and Clinical Research, 1990, 16, 569-74.	0.3	2
63	Excretion of the Polymyxin Derivative NAB739 in Murine Urine. Antibiotics, 2020, 9, 143.	3.7	1
64	CP-089â€The effect of the blood culture result on subsequent antimicrobial treatment in paediatric hospital-acquired infections. European Journal of Hospital Pharmacy, 2014, 21, A36.1-A36.	1.1	0
65	Title is missing!. , 2020, 15, e0232775.		0
66	Title is missing!. , 2020, 15, e0232775.		0
67	Title is missing!. , 2020, 15, e0232775.		Ο
68	Title is missing!. , 2020, 15, e0232775.		0
69	Title is missing!. , 2020, 15, e0232775.		0
70	Title is missing!. , 2020, 15, e0232775.		0